A systematic FDA regulatory review standardized bioequivalence administration protocols across product-specific guidances for ...
The agency describes the requirements for retaining reserve samples of test articles and reference standards used in an in-vivo bioavailability and in-vivo or in-vitro bioequivalence study. The ...
Given data integrity issues that have been uncovered in the past, in April 2024, the U.S. Food and Drug Administration (FDA) published a draft guidance to applicants and testing site management on ...
The US Food and Drug Administration (FDA) on Friday finalized guidance for sponsors who wish to request a waiver of an in vivo bioavailability (BA) and/or bioequivalence (BE) study requirements for ...
The US Food and Drug Administration (FDA) has published a new draft guidance recommending various approaches when conducting bioequivalence (BE) and bioavailability (BA) studies in support of new and ...
Incannex has received approval from Bellberry Human Research Ethics Committee ('HREC') to commence the bioavailability/bioequivalence ('BA/BE') clinical trial to ...
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, April 07, 2025 (GLOBE NEWSWIRE) -- The "Bioavailability and Bioequivalence Studies submitted in NDAs and INDs" training has been added to ...
The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...
A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data ...
To allay these concerns, the FDA stated that differences in tablet content or bioavailability among therapeutically equivalent products should never exceed 9%, and the actual differences were more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results